Presentation is loading. Please wait.

Presentation is loading. Please wait.

Ted D. Williams PharmD Candidate OSU College of Pharmacy

Similar presentations


Presentation on theme: "Ted D. Williams PharmD Candidate OSU College of Pharmacy"— Presentation transcript:

1 Ted D. Williams PharmD Candidate OSU College of Pharmacy
Basal Insulin Therapy Ted D. Williams PharmD Candidate OSU College of Pharmacy

2 Initiating Insulin Therapy
GC Type 2 Diabetic for 10 years is maxed out on Metformin and glyburide AM FBG 275, A1C 10% PCP orders glargine titration CC AM FBG 90, A1C 9.0%

3 Modifying Insulin Therapy
CB Type 2 Diabetic for 3 years Taking 1000mg Metformin BID, 10mg glyburide BID, NPH 10units QPM Complains of daytime hypoglycemia PCP orders D/C NPH and convert to detemir 10units QPM A1C 7%, FBG 120 LS Type 2 Diabetic for 5 years Taking 1700mg Metformin XR QPM, 5mg glyburide BID, NPH 10 units QPM Complains of nighttime hypoglycemia A1C 7%, FBG 60

4 Switching to Insulin Therapy
Type 2 diabetes for 8 years Metformin 500mg BID, Glyburide 10mg BID A1C 8%, FBG 170 PCP orders D/C Glyburide 10mg BID and begin detemir titration based on PREDICTIVE Trial which shows detemir has better control, less weight gain, and less hypoglycemia than glyburide

5 Objectives Pathophysiology Kinetics of insulin analogs
Normal Insulin Patterns Type I vs. Type II Diabetes Compare normal and diabetic insulin secretion patterns Kinetics of insulin analogs Laboratory values and relevance to pharmacotherapy Compare intermediate and long acting insulin analogs Review and summarize recent clinical trials on intermediate and long acting insulin therapy

6 Prandial Insulin Release
Timing is Everything Prandial Insulin Release Basal Insulin Release

7 Pathophysiology of Type 1 vs. Type 2 Diabetes
Autoimmune Response, destroying insulin secreting islet cells (beta cells) of the pancreas Rapid onset, usually early in life (<30 years) Total insulin dependence No insulin resistance Low insulin supplementation Type 2 Progressive insulin resistance in peripheral cells lead to increased insulin secretion to maintain blood glucose Insidious onset, usually later in life (>30 years) Increased insulin demand lead to “burn out” of beta cells of the pancreas and can lead to total insulin dependence over time High insulin supplementation

8 Type 2 Compensation and Exhaustion

9 Goals of Therapy Goal Strategy
Stabilize Glucose levels within ~ mg/dL or 4-7mmol/L Strategy Mimic non-diabetic insulin patterns in patients with abnormal insulin homeostasis Increase insulin sensitivity in insulin resistant patients Today’s focus will be on insulin pattern management only

10 Ideal Insulin Replacement Strategy
Bolus Insulin Basal Insulin

11 Type 1 Insulin Management
Goals Replace Insulin Prandial (meal time) insulin supplementation Basal (liver) supplementation Strategies Basal/Bolus Insulin injections Rapid acting mealtime insulin Slow acting basal insulin Insulin Pumps Filled with rapid acting insulin Vary rate based on actual/anticipated blood glucose levels Our talk will focus on Type 2 diabetes

12 Tools of the Trade Insulin Analogs Oral Agents
Mimic endogenous insulin Modified kinetics Oral Agents Modify insulin sensitivity Modify glucose absorption/secretion Modify insulin secretion

13 Type 2 Diabetes Treatment
Insulin is almost always add on therapy

14 Timing is everything – Insulin Preparations
Onset (hr) Peak (hr) Duration (hr) Lispro, Aspart, Glulisine <0.25 1-2 3-4 Regular 0.5-1 2-3 3-6 NPH 2-4 4-10 10-16 Glargine Flat 24 Detemir 12-24 Diabetes Forecast – 2008 Resource Guide (ADA)

15 Blood Glucose Management – Monitoring
So how do we measure efficacy of therapy? Fasting Blood/Plasma Glucose (FBG/FPG) Post Prandial Blood Glucose Glycosylated Hemoglobin A1C (A1C) Hypoglycemia Incidents

16 Diabetes Metrics – Blood Glucose
Target Range mg/dL 4-7 mmol/L Post Prandial (after meal) Was bolus adequate? Fasting Plasma Glucose Taken in the morning Was basal adequate?

17 Diabetes Metrics – A1C Rough 3 month average of blood glucose
Weighted more heavily to the last month Good for validating patient’s home monitoring Good for estimating post prandial glucose control in patients only measuring FBG False “Normal” values can occur in patients with hypoglycemia and hyperglycemia

18 Matching FBG and A1C 7% A1C = 170mg/dL +/-1% A1C = +/- 35mg/dL

19 Diabetes Metrics – Hypoglycemic Events
Events indicate too much insulin Daytime suggests bolus may be too high Nighttime suggest basal may be too high

20 Initiating Insulin Therapy
GC Type 2 Diabetic for 10 years is maxed out on Metformin and glyburide AM FBG 275, A1C 10% PCP orders glargine titration Recommendation Basal insulin (glargine) is reasonable Both basal (FBG) and post prandial (A1C) elevated, more insulin all the time seems like a good idea

21 Initiating insulin Therapy
CC Type 2 Diabetic for 10 years is maxed out on Metformin and glyburide AM FBG 90, A1C 9.0% PCP orders glargine titration Recommendation Low FBG suggest basal insulin is adequate High A1C suggest post-prandial glucose is not well controlled Basal insulin more likely to precipitate hypoglycemia before target A1C is achieved

22 Long Acting Insulin Choices
Onset (hr) Peak (hr) Duration (hr) Lispro, Aspart, Glulisine <0.25 1-2 3-4 Regular 0.5-1 2-3 3-6 NPH 2-4 4-10 10-16 Glargine Flat 24 Detemir 12-24 Diabetes Forecast – 2008 Resource Guide (ADA)

23 Longer Acting Insulin Pharmacology
ToDo

24 Longer Acting Insulin Kinetics
NPH Glargine Detemir Adapted from: Lower Within-Subject Variability of Insulin Detemir in Comparison to NPH Insulin and Insulin Glargine in People With Type 1 Diabetes, Heise et al DIABETES 2004;53:

25 NPH Insulin Kinetics Normal Insulin Levels Adv. DM2 Insulin Production
Isolated NPH Curve NPH Insulin Shift

26 NPH Results Provides intermediate duration, delayed insulin peak
Peak and onset delay are significant Intra-patient variability somewhat high Good for patients with combination Post Prandial and Basal Hyperglycemia Good for nighttime coverage, esp. compared to Regular insulin

27 Glargine/Detemir Insulin Kinetics
Normal Insulin Levels Reduced Insulin Production Basal Insulin Shift

28 Glargine/Detemir Insulin Results
Glargine or detemir recommended for patients who experience nocturnal hypoglycemia VA/DoD clinical practice guideline for the management of diabetes mellitus (2003) Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus (Review) Horvath et al (The Cochrane Collaboration 2008) No statistically significant difference in Morbidity and Mortality data, i.e. efficacy

29 Modifying Insulin Therapy
CB Type 2 Diabetic for 3 years Taking 1000mg Metformin BID, 10mg glyburide BID, NPH 10units QPM Complains of daytime hypoglycemia PCP orders D/C NPH and convert to glargine 10units QPM A1C 7%, FBG 120 Recommendation NPH only lasts about hours, adding a longer duration insulin at night will increase daytime hypoglycemia Consider reducing glyburide (secretalogue) dose

30 Modifying Insulin Therapy
LS Type 2 Diabetic for 5 years Taking 1700mg Metformin XR QPM, 5mg glyburide BID, NPH 10 units QPM Complains of nighttime hypoglycemia A1C 7%, FBG 60 PCP orders D/C NPH and convert to detemir 10units QPM Recommendation NPH has a higher incidence of nighttime hypoglycemia vs. detemir Switch sounds like a good idea

31 Which is Better… Published head to head trials with detemir and glargine are limited Type 1 & Type 2 each have 1 good study Detemir demonstrated non-inferiority to glargine Once daily dosing of glargine and detemir have similar volumes Some patients (~50%) will require BID detemir dosing, which typically doubles the daily dose There appears to be more injection site issues with detemir vs glargine No other efficacy or safety outcomes are clearly better or worse Rosenstock, et al A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose lowering drugs in insulin naïve people with type-2 diabetes. Diabetologia 2008: 51; Pieber, et al: Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy. Diabetic Medicine 2007; 24:

32 Review of some…“Evidence”

33 PREDICTIVE Study Commonly sited in second tier journals and review articles Very large study 30,000 patients Purportedly an observational study comparing detemir vs NPH and/or glargine

34 PREDICTIVE Study – biases
Study sponsored by Novo Nordisk That’s the detemir folks Only subgroup analyses have been published Cherry picking Single arm, observational studies Translation: improvements from baseline are portrayed as superior therapy Participating Physicians paid for participation Form of kickback for prescribing MDs No discussion in power Statistics don’t lie: No power calculations, no valid p values, no significant results Investigator Bias All authors are direct employees or are consultants to Novo Nordisk

35 PREDICTIVE Study – Evidence Level
Observational Studies Do not establish cause and effect relationships No placebo, active control, or standard of care comparisons The published data as been poorly designed, obviously biased, used inappropriate statistical methods

36 Switching to Insulin Therapy
Type 2 diabetes for 8 years Metformin 500mg BID, Glyburide 10mg BID A1C 8%, FBG 170 PCP orders D/C Glyburide 10mg BID and begin detemir titration based on PREDICTIVE Trial which shows detemir has better control, less weight gain, and less hypoglycemia than glyburide Recommendations PREDICTIVE is an uncontrolled, biased, observational study and it more marketing than research Suggest increase Metformin, continue glyburide, and hold detemir Take it to Eleven

37 Summary Points Insulin detemir and glargine are for basal insulin management with delayed onset and long duration Basal insulin therapy is best for Type 1 Diabetics or advanced Type 2 Diabetics who have limited or no endogenous insulin secretion Insulin detemir and glargine are equally efficacious to NPH for basal insulin control Insulin detemir and glargine have lower incidence of nocturnal hypoglycemia than NPH There is no evidence to show either detemir or glargine is superior to the other in side effects or efficacy

38 Questions


Download ppt "Ted D. Williams PharmD Candidate OSU College of Pharmacy"

Similar presentations


Ads by Google